Ligand Pharmaceuticals (LGND) Income towards Parent Company (2010 - 2026)

Ligand Pharmaceuticals has reported Income towards Parent Company for 15 years, with the latest figure at -$13.3 million in Q1 2026.

• Quarterly Income towards Parent Company rose 68.56% year-over-year to -$13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (up 308.81% YoY) and the FY2025 annual result came in at $124.5 million, up 3186.63% from the prior year.
• Income towards Parent Company fell to -$13.3 million in Q1 2026 per LGND's latest filing, from $44.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $117.3 million in Q3 2025 and troughed at -$42.5 million in Q1 2025.
• A 5-year average of $4.6 million and a median of -$3.0 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company tumbled 136.03% in 2022, then jumped 244.06% in 2025.
• Over 5 years, Income towards Parent Company stood at -$3.0 million in 2022, then surged by 43.58% to -$1.7 million in 2023, then sank by 1767.15% to -$31.1 million in 2024, then surged by 244.06% to $44.8 million in 2025, then tumbled by 129.8% to -$13.3 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$13.3 million, $44.8 million, and $117.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.